CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Sarepta Therapeutics, Inc. - SRPT CFD

124.09
0.91%
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.55
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024262 %
Charges from full value of position ($-4.61)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00204 %
Charges from full value of position ($0.39)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00204%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 125.23
Open 125.55
1-Year Change 43.31%
Day's Range 123.69 - 125.55
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 11, 2024 125.23 -0.67 -0.53% 125.90 127.35 124.25
Dec 10, 2024 126.50 -0.45 -0.35% 126.95 128.69 125.69
Dec 9, 2024 128.57 0.96 0.75% 127.61 130.69 127.45
Dec 6, 2024 127.94 1.64 1.30% 126.30 128.81 125.45
Dec 5, 2024 126.00 0.55 0.44% 125.45 127.64 123.71
Dec 4, 2024 126.09 0.13 0.10% 125.96 127.83 124.65
Dec 3, 2024 125.62 -1.28 -1.01% 126.90 128.02 124.95
Dec 2, 2024 127.45 -3.87 -2.95% 131.32 131.80 125.17
Nov 29, 2024 132.70 -3.10 -2.28% 135.80 138.35 132.70
Nov 27, 2024 136.94 6.83 5.25% 130.11 137.81 129.95
Nov 26, 2024 129.96 13.88 11.96% 116.08 130.47 114.60
Nov 25, 2024 114.27 1.51 1.34% 112.76 115.14 112.76
Nov 22, 2024 114.13 3.58 3.24% 110.55 114.40 109.96
Nov 21, 2024 110.43 -0.38 -0.34% 110.81 111.16 108.63
Nov 20, 2024 110.75 0.27 0.24% 110.48 111.23 108.48
Nov 19, 2024 106.57 3.11 3.01% 103.46 106.83 103.46
Nov 18, 2024 104.61 1.73 1.68% 102.88 105.75 101.80
Nov 15, 2024 104.47 -4.09 -3.77% 108.56 108.56 102.50
Nov 14, 2024 108.67 -3.10 -2.77% 111.77 112.01 108.67
Nov 13, 2024 112.36 -1.29 -1.14% 113.65 115.89 111.49

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sarepta Company profile

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry: Bio Therapeutic Drugs

215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US

People also watch

XRP/USD

2.35 Price
-4.000% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01170

Gold

2,680.88 Price
-1.360% 1D Chg, %
Long position overnight fee -0.0160%
Short position overnight fee 0.0078%
Overnight fee time 22:00 (UTC)
Spread 0.30

ETH/USD

3,858.92 Price
+0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

100,005.55 Price
-1.680% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading